CR20170275A - 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 - Google Patents

4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139

Info

Publication number
CR20170275A
CR20170275A CR20170275A CR20170275A CR20170275A CR 20170275 A CR20170275 A CR 20170275A CR 20170275 A CR20170275 A CR 20170275A CR 20170275 A CR20170275 A CR 20170275A CR 20170275 A CR20170275 A CR 20170275A
Authority
CR
Costa Rica
Prior art keywords
gpr139
benzotriazinas
dihidro
modulators
oxo
Prior art date
Application number
CR20170275A
Other languages
English (en)
Inventor
Holly Reichard
Holger Monenschein
Betty Lam
Stephen Hitchcock
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CR20170275A publication Critical patent/CR20170275A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un método para tratar una enfermedad, trastorno o afección asociado con GPR139 utilizando compuestos de fórmula 1: los cuales son agonistas de GPR139, ciertos compuestos englobados por la fórmula 1, composiciones farmacéuticas de estos, procesos para preparar los compuestos e intermedios de estos.
CR20170275A 2014-11-20 2015-11-19 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 CR20170275A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462082539P 2014-11-20 2014-11-20
US201562184729P 2015-06-25 2015-06-25
PCT/US2015/061607 WO2016081736A1 (en) 2014-11-20 2015-11-19 4-oxo-3,4-dihydro-1,2,3-benzotriazines as modulators of gpr139

Publications (1)

Publication Number Publication Date
CR20170275A true CR20170275A (es) 2017-10-30

Family

ID=55022667

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170275A CR20170275A (es) 2014-11-20 2015-11-19 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139

Country Status (39)

Country Link
US (5) US9556130B2 (es)
EP (2) EP3221298B1 (es)
JP (2) JP6637501B2 (es)
KR (1) KR102582021B1 (es)
CN (2) CN107108531B (es)
AU (1) AU2015349866B2 (es)
CA (1) CA2968242C (es)
CL (1) CL2017001292A1 (es)
CO (1) CO2017005959A2 (es)
CR (1) CR20170275A (es)
CY (2) CY1122613T1 (es)
DK (2) DK3536324T3 (es)
DO (1) DOP2017000120A (es)
EA (1) EA033728B1 (es)
EC (1) ECSP17038999A (es)
ES (2) ES2734735T3 (es)
GE (1) GEP20196961B (es)
HR (2) HRP20212009T1 (es)
HU (2) HUE044145T2 (es)
IL (1) IL252311B (es)
JO (1) JO3719B1 (es)
LT (2) LT3221298T (es)
MA (1) MA40993B1 (es)
MD (1) MD3221298T2 (es)
MX (1) MX2017006448A (es)
MY (1) MY187423A (es)
NZ (1) NZ732208A (es)
PE (1) PE20170899A1 (es)
PH (1) PH12017500920B1 (es)
PL (2) PL3536324T3 (es)
PT (2) PT3536324T (es)
RS (2) RS62563B1 (es)
SG (1) SG11201704002UA (es)
SI (2) SI3536324T1 (es)
TN (1) TN2017000196A1 (es)
TW (1) TWI684590B (es)
UA (1) UA120375C2 (es)
UY (1) UY36406A (es)
WO (1) WO2016081736A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
US12042496B2 (en) 2018-10-16 2024-07-23 The University Of Florida Research Foundation, Incorporated Methods related to opioid therapeutics
WO2020097609A1 (en) * 2018-11-09 2020-05-14 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
TW202124386A (zh) 2019-09-16 2021-07-01 日商武田藥品工業股份有限公司 唑稠合之嗒-3(2h)-酮衍生物
WO2021127459A1 (en) * 2019-12-20 2021-06-24 Blackthorn Therapeutics, Inc. Gpr139 receptor modulators
EP4146635A1 (en) * 2020-05-08 2023-03-15 Takeda Pharmaceutical Company Limited Substituted benzotriazinone metabolites of a gpr139 agonist
EP4213853A1 (en) 2020-09-21 2023-07-26 Takeda Pharmaceutical Company Limited Treatment for schizophrenia
US11760788B2 (en) 2021-03-02 2023-09-19 Pathways Neuro Pharma, Inc. Neuroreceptor compositions and methods of use
CN116693545A (zh) * 2022-03-01 2023-09-05 上海科技大学 噻吩并含氮杂环类化合物、含其的药物组合物、其制备方法及其应用
WO2023165263A1 (zh) * 2022-03-01 2023-09-07 上海科技大学 吡咯并三嗪酮类化合物、含其的药物组合物、其制备方法及其应用
CN117986183A (zh) * 2022-10-28 2024-05-07 浙江友宁生物医药科技有限公司 一种gpr139受体激动剂、其制备方法及其应用
WO2024102802A1 (en) * 2022-11-11 2024-05-16 Takeda Pharmaceutical Company Limited Zelatriazin for the treatment of depression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3794726A (en) 1972-08-21 1974-02-26 Uniroyal Inc Inhibiting aggressive behavior with 1,2,3-benzotriazin-(3h)-one
DE3752141T2 (de) 1986-02-24 1998-03-26 Mitsui Petrochemical Ind Mittel zur behandlung von neuropathie
ATE108791T1 (de) * 1987-11-04 1994-08-15 Beecham Group Plc Neue 4-oxobenzotriazine und 4-oxochinazoline.
EP1636200A2 (en) 2003-06-09 2006-03-22 Boehringer Ingelheim International GmbH Inhibitors of papilloma virus
JP2007500728A (ja) 2003-07-31 2007-01-18 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｐｄｆインヒビターとしての二環式化合物および組成物
FR2875805B1 (fr) 2004-09-27 2006-12-29 Genfit S A Composes derives de n-(benzyl) phenylacetamide substitues, preparation et utilisations
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
MX2009010218A (es) * 2007-03-23 2009-10-19 Hoffmann La Roche Derivados de aza-piridopirimidinona.
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
WO2014152917A2 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv Physiological ligands for gpr139
JO3719B1 (ar) * 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139

Also Published As

Publication number Publication date
SG11201704002UA (en) 2017-06-29
SI3221298T1 (sl) 2019-10-30
HUE057451T2 (hu) 2022-05-28
KR20170084324A (ko) 2017-07-19
ES2734735T3 (es) 2019-12-11
PH12017500920A1 (en) 2017-11-20
CN112062730B (zh) 2023-09-29
CO2017005959A2 (es) 2017-10-20
HUE044145T2 (hu) 2019-09-30
DK3221298T3 (da) 2019-06-24
MD3221298T2 (ro) 2019-10-31
TN2017000196A1 (en) 2018-10-19
DK3536324T3 (da) 2021-10-25
ECSP17038999A (es) 2017-10-31
IL252311B (en) 2020-07-30
CA2968242A1 (en) 2016-05-26
TW201625566A (zh) 2016-07-16
NZ732208A (en) 2023-02-24
US9556130B2 (en) 2017-01-31
PT3536324T (pt) 2021-11-10
CY1124929T1 (el) 2023-01-05
HRP20191003T1 (hr) 2019-08-23
EP3221298B1 (en) 2019-04-03
UA120375C2 (uk) 2019-11-25
US20160145218A1 (en) 2016-05-26
US20170348319A1 (en) 2017-12-07
TWI684590B (zh) 2020-02-11
US20200129518A1 (en) 2020-04-30
RS62563B1 (sr) 2021-12-31
LT3221298T (lt) 2019-08-12
BR112017010311A2 (pt) 2017-12-26
CN107108531A (zh) 2017-08-29
US20170095480A1 (en) 2017-04-06
US11173161B2 (en) 2021-11-16
PT3221298T (pt) 2019-06-28
PL3221298T3 (pl) 2019-10-31
PE20170899A1 (es) 2017-07-12
US10159677B2 (en) 2018-12-25
CL2017001292A1 (es) 2018-02-16
MA40993B1 (fr) 2019-07-31
EP3536324B1 (en) 2021-10-06
EP3536324A1 (en) 2019-09-11
PH12017500920B1 (en) 2017-11-20
DOP2017000120A (es) 2017-06-15
WO2016081736A1 (en) 2016-05-26
JP2017535559A (ja) 2017-11-30
AU2015349866A1 (en) 2017-06-15
CN107108531B (zh) 2020-10-20
CY1122613T1 (el) 2021-05-05
RS59078B1 (sr) 2019-09-30
EA201791096A1 (ru) 2017-11-30
EP3221298A1 (en) 2017-09-27
MX2017006448A (es) 2017-09-12
UY36406A (es) 2016-06-30
AU2015349866B2 (en) 2020-12-03
ES2897545T3 (es) 2022-03-01
GEP20196961B (en) 2019-03-25
US20190070187A1 (en) 2019-03-07
IL252311A0 (en) 2017-07-31
HRP20212009T1 (hr) 2022-04-01
JP6918088B2 (ja) 2021-08-11
EA033728B1 (ru) 2019-11-20
MY187423A (en) 2021-09-22
KR102582021B1 (ko) 2023-09-22
US10561662B2 (en) 2020-02-18
SI3536324T1 (sl) 2021-12-31
US9770450B2 (en) 2017-09-26
MA40993A (fr) 2017-09-27
JP6637501B2 (ja) 2020-01-29
JP2020063285A (ja) 2020-04-23
CA2968242C (en) 2022-11-08
JO3719B1 (ar) 2021-01-31
CN112062730A (zh) 2020-12-11
PL3536324T3 (pl) 2022-02-07
LT3536324T (lt) 2021-12-10

Similar Documents

Publication Publication Date Title
DOP2017000120A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CL2018000375A1 (es) 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
CO2018005954A2 (es) Compuestos heteroaromáticos como inhibidores de btk
CO2017000065A2 (es) Indoles funcionalizados y sustituidos como agentes anti-cáncer
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CO2020000227A2 (es) Moduladores de nlrp3
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CL2017000151A1 (es) Derivados de piridona
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
CL2016002515A1 (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1.
CL2016001745A1 (es) Ácido (s)-3'-metil-abscísico y ésteres del mismo